Blaine Hackman focuses his practice on post-grant proceedings before the US Patent and Trademark Office (USPTO), and related patent litigation, prosecution, and counseling. Blaine regularly represents clients in inter partes review (IPR) and post-grant review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB), with an emphasis on biotechnology and pharmaceutical technologies.
In addition to his active post-grant proceedings practice, Blaine works with clients on the full spectrum of their intellectual property needs. He has experience representing pharmaceutical and biotechnology clients in intellectual property litigation (including Hatch-Waxman proceedings) and advising clients on patent issues, including patentability and freedom-to-operate (FTO) evaluations. He has also prosecuted patents and counseled clients in transactions in a variety of technologies, including small molecule and protein therapies, nanotechnology, diagnostic imaging, and analytical chemistry.
Blaine actively publishes, presents, and provides insights to the media on intellectual property-related issues.
- Represented petitioner, a clinical stage pharmaceutical company, a PGR challenging a patent claiming therapeutic compounds related targeted protein degradation, which led to patent owner’s disclaimer of the challenged patent.
- Represented petitioner, a clinical stage biopharmaceutical company, in two IPRs challenging to patents related to protein mimetics, which led to a favorable confidential settlement.
- Represented a major biotechnology company as defendant/petitioner in co-pending district court and PGR proceedings relating to a monoclonal antibody therapy, which resulted in entry of adverse judgment in the PGR with cancellation of the asserted patent and dismissal of the district court case.
- Represented a specialty pharmaceutical company as plaintiff/patent owner in co-pending district court Hatch-Waxman litigations and multiple IPR proceedings, which resulted in the denial of institution for all IPRs and favorable district court settlements.
- Represented a major pharmaceutical company in securing a reissue patent in the USPTO covering its blockbuster cancer treatment.
- Advised a major investor in pharmaceutical and biotechnology royalty streams on patent issues for several transactions.
- Patent Trial and Appeal Board (PTAB) Bar Association
- American Chemical Society
- Named to the list of New York Rising Stars by Super Lawyers (2017-2022)
- Recognized by Licensing Executive Society International Journal, les Nouvelles, for publishing an Article of the Month (2014)
- Dow Chemical Foundation Scholar, Harvey Mudd College
Chief Judge Prost: A Defender of Clarity in Patent Law | Wolf Greenfield
PTAB Mylan Decision Could Be Boon To Drug Innovators | Wolf Greenfield
Expert Discovery Protections: Comparing District Courts with the PTAB | Wolf Greenfield
Wolf Greenfield Attorneys Named to 2022 New York Super Lawyers, Rising Stars Lists | Wolf Greenfield
Blaine Hackman Quoted by Law360 on a New PTAB Process | Wolf Greenfield
Blaine Hackman Quoted by Bloomberg Law on Drugmakers Undercutting Rivals With New Patent Tactic as Law Shifts | Wolf Greenfield
BPLA’s Annual IP Symposium: 2022 Trends at the PTAB
June 2, 2022 | Virtual